Home > Publications database > Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts. > print

001     186561
005     20240229154900.0
024 7 _ |a 10.1007/s10654-022-00921-1
|2 doi
024 7 _ |a pmid:36593337
|2 pmid
024 7 _ |a 0393-2990
|2 ISSN
024 7 _ |a 1573-7284
|2 ISSN
024 7 _ |a altmetric:140764888
|2 altmetric
037 _ _ |a DKFZ-2023-00013
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Visvanathan, Kala
|b 0
245 _ _ |a Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts.
260 _ _ |a Dordrecht [u.a.]
|c 2023
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1674658209_18725
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Jan;38(1):11-29
520 _ _ |a Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42-68) years at blood collection and 63 (49-75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64). Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50- < 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations (< 20 nmol/L, 3% of controls) or high concentrations (100- < 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95-1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection. Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a 25-Hydroxyvitamin D
|2 Other
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Calibration
|2 Other
650 _ 7 |a Pooled analysis
|2 Other
650 _ 7 |a Prospective cohort study
|2 Other
650 _ 7 |a Vitamin D
|2 Other
700 1 _ |a Mondul, Alison M
|b 1
700 1 _ |a Zeleniuch-Jacquotte, Anne
|b 2
700 1 _ |a Wang, Molin
|b 3
700 1 _ |a Gail, Mitchell H
|b 4
700 1 _ |a Yaun, Shiaw-Shyuan
|b 5
700 1 _ |a Weinstein, Stephanie J
|b 6
700 1 _ |a McCullough, Marjorie L
|b 7
700 1 _ |a Eliassen, A Heather
|b 8
700 1 _ |a Cook, Nancy R
|b 9
700 1 _ |a Agnoli, Claudia
|b 10
700 1 _ |a Almquist, Martin
|b 11
700 1 _ |a Black, Amanda
|b 12
700 1 _ |a Buring, Julie E
|b 13
700 1 _ |a Chen, Chu
|b 14
700 1 _ |a Chen, Yu
|b 15
700 1 _ |a Clendenen, Tess
|b 16
700 1 _ |a Dossus, Laure
|b 17
700 1 _ |a Fedirko, Veronika
|b 18
700 1 _ |a Gierach, Gretchen L
|b 19
700 1 _ |a Giovannucci, Edward L
|b 20
700 1 _ |a Goodman, Gary E
|b 21
700 1 _ |a Goodman, Marc T
|b 22
700 1 _ |a Guénel, Pascal
|b 23
700 1 _ |a Hallmans, Göran
|b 24
700 1 _ |a Hankinson, Susan E
|b 25
700 1 _ |a Horst, Ronald L
|b 26
700 1 _ |a Hou, Tao
|b 27
700 1 _ |a Huang, Wen-Yi
|b 28
700 1 _ |a Jones, Michael E
|b 29
700 1 _ |a Joshu, Corrine E
|b 30
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 31
|u dkfz
700 1 _ |a Krogh, Vittorio
|b 32
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 33
700 1 _ |a Kvaskoff, Marina
|b 34
700 1 _ |a Lee, I-Min
|b 35
700 1 _ |a Mahamat-Saleh, Yahya
|b 36
700 1 _ |a Malm, Johan
|b 37
700 1 _ |a Manjer, Jonas
|b 38
700 1 _ |a Maskarinec, Gertraud
|b 39
700 1 _ |a Millen, Amy E
|b 40
700 1 _ |a Mukhtar, Toqir K
|b 41
700 1 _ |a Neuhouser, Marian L
|b 42
700 1 _ |a Robsahm, Trude E
|b 43
700 1 _ |a Schoemaker, Minouk J
|b 44
700 1 _ |a Sieri, Sabina
|b 45
700 1 _ |a Sund, Malin
|b 46
700 1 _ |a Swerdlow, Anthony J
|b 47
700 1 _ |a Thomson, Cynthia A
|b 48
700 1 _ |a Ursin, Giske
|b 49
700 1 _ |a Wactawski-Wende, Jean
|b 50
700 1 _ |a Wang, Ying
|b 51
700 1 _ |a Wilkens, Lynne R
|b 52
700 1 _ |a Wu, Yujie
|b 53
700 1 _ |a Zoltick, Emilie
|b 54
700 1 _ |a Willett, Walter C
|b 55
700 1 _ |a Smith-Warner, Stephanie A
|b 56
700 1 _ |a Ziegler, Regina G
|0 0000-0002-5100-9852
|b 57
773 _ _ |a 10.1007/s10654-022-00921-1
|0 PERI:(DE-600)2004992-4
|n 1
|p 11-29
|t European journal of epidemiology
|v 38
|y 2023
|x 0393-2990
909 C O |p VDB
|o oai:inrepo02.dkfz.de:186561
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-17
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-17
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21